Symbols / TNGX
TNGX Chart
About
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.74B |
| Enterprise Value | 1.62B | Income | -100.52M | Sales | 66.50M |
| Book/sh | 1.43 | Cash/sh | 1.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 155 | IPO | — |
| P/E | — | Forward P/E | -9.52 | PEG | — |
| P/S | 26.23 | P/B | 9.03 | P/C | — |
| EV/EBITDA | -14.97 | EV/Sales | 24.29 | Quick Ratio | 8.29 |
| Current Ratio | 8.88 | Debt/Eq | 21.72 | LT Debt/Eq | — |
| EPS (ttm) | -0.91 | EPS next Y | -1.36 | EPS Growth | — |
| Revenue Growth | 3.64% | Earnings | 2026-03-05 | ROA | -24.52% |
| ROE | -51.65% | ROIC | — | Gross Margin | -101.50% |
| Oper. Margin | 26.15% | Profit Margin | -151.15% | Shs Outstand | 134.68M |
| Shs Float | 59.72M | Short Float | 39.45% | Short Ratio | 14.10 |
| Short Interest | — | 52W High | 13.48 | 52W Low | 1.03 |
| Beta | 1.76 | Avg Volume | 2.83M | Volume | 489.38K |
| Target Price | $15.67 | Recom | Strong_buy | Prev Close | $12.88 |
| Price | $12.95 | Change | 0.54% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.67
Mean price target
2. Current target
$12.88
Latest analyst target
3. DCF / Fair value
$-8.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.88
Low
$13.00
High
$19.00
Mean
$15.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | init | Mizuho | — → Outperform | $19 |
| 2026-02-06 | main | Guggenheim | Buy → Buy | $18 |
| 2026-01-16 | main | Piper Sandler | Overweight → Overweight | $14 |
| 2025-12-04 | init | Stifel | — → Buy | $15 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-11-18 | main | B. Riley Securities | Buy → Buy | $14 |
| 2025-10-24 | main | Guggenheim | Buy → Buy | $12 |
| 2025-08-19 | init | Piper Sandler | — → Overweight | $11 |
| 2025-08-06 | main | Guggenheim | Buy → Buy | $10 |
| 2025-04-14 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-12-05 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-11-11 | main | B. Riley Securities | Buy → Buy | $8 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-11-07 | main | Guggenheim | Buy → Buy | $8 |
| 2024-10-28 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-08-08 | main | Wedbush | Outperform → Outperform | $13 |
| 2024-07-17 | init | Jefferies | — → Buy | $19 |
| 2024-07-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-07-09 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
- $TNGX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 14
- Mizuho Initiates Coverage of Tango Therapeutics (TNGX) with Outperform Recommendation - Nasdaq Mon, 23 Feb 2026 20
- Mizuho initiates Tango Therapeutics stock with outperform rating - Investing.com Mon, 23 Feb 2026 10
- Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - Yahoo Finance Wed, 17 Sep 2025 07
- Tango Therapeutics (NASDAQ: TNGX) prices equity offering and PIPE for $225M total - Stock Titan hu, 23 Oct 2025 07
- With Tango Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis Sat, 20 Dec 2025 08
- Tango Therapeutics CFO sells $126,530 in TNGX stock - Investing.com Wed, 04 Feb 2026 08
- Insider Sale: Chief Financial Officer of $TNGX Sells 113 Shares - Quiver Quantitative hu, 05 Feb 2026 08
- Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - Yahoo Finance Fri, 21 Nov 2025 08
- Commit To Purchase Tango Therapeutics At $10, Earn 25.9% Annualized Using Options - Nasdaq Wed, 04 Feb 2026 08
- Tango Therapeutics (NASDAQ: TNGX) to join Jefferies Healthcare Conf. Nov. 19; 90-day replay - Stock Titan Wed, 12 Nov 2025 08
- Assessing Tango Therapeutics (TNGX) Valuation After 170% Share Price Rally and Recent Pullback - Yahoo Finance hu, 23 Oct 2025 07
- Tango Therapeutics Announces Pricing of $210 Million Underwritten Offering and $15 Million PIPE Financing - Quiver Quantitative hu, 23 Oct 2025 07
- $TNGX stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Weber Barbara, director at Tango Therapeutics, sells $374k in TNGX stock - Investing.com Australia hu, 05 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10317 | 126531 | — | Sale at price 12.26 - 12.90 per share. | BECKMAN DANIELLA | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 1 | 30519 | 374294 | — | Sale at price 12.26 - 12.90 per share. | WEBER BARBARA L | Officer and Director | — | 2026-02-03 00:00:00 | D |
| 2 | 18452 | 226300 | — | Sale at price 12.26 - 12.90 per share. | CRYSTAL ADAM S | Officer | — | 2026-02-03 00:00:00 | D |
| 3 | 44330 | — | — | Stock Award(Grant) at price 0.00 per share. | BECKMAN DANIELLA | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 37522 | — | — | Stock Award(Grant) at price 0.00 per share. | WEBER BARBARA L | Officer and Director | — | 2026-02-02 00:00:00 | D |
| 5 | 47460 | — | — | Stock Award(Grant) at price 0.00 per share. | CRYSTAL ADAM S | Officer | — | 2026-02-02 00:00:00 | D |
| 6 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | PETERS MALTE | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 7 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEE SUNG | Director | — | 2026-01-02 00:00:00 | D |
| 8 | 477401 | 3594830 | — | Sale at price 7.53 per share. | THIRD ROCK VENTURES IV, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-23 00:00:00 | I |
| 9 | 500000 | 4008500 | — | Sale at price 8.02 per share. | THIRD ROCK VENTURES IV, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-25 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -143.10M | -111.76M | -109.46M | -57.29M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -130.30M | -101.74M | -108.18M | -58.23M |
| ReconciledDepreciation | 2.50M | 2.42M | 1.61M | 897.00K |
| EBITDA | -143.10M | -111.76M | -109.46M | -57.29M |
| EBIT | -145.59M | -114.17M | -111.07M | -58.19M |
| NetInterestIncome | 7.89M | 6.62M | 1.46M | 495.00K |
| InterestIncome | 7.89M | 6.62M | 1.46M | 495.00K |
| NormalizedIncome | -130.30M | -101.74M | -108.18M | -58.23M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -130.30M | -101.74M | -108.18M | -58.23M |
| TotalExpenses | 187.66M | 150.70M | 135.93M | 95.23M |
| TotalOperatingIncomeAsReported | -145.59M | -114.17M | -111.07M | -58.19M |
| DilutedAverageShares | 109.23M | 94.57M | 87.82M | 62.11M |
| BasicAverageShares | 109.23M | 94.57M | 87.82M | 62.11M |
| DilutedEPS | -1.19 | -1.08 | -1.23 | -0.94 |
| BasicEPS | -1.19 | -1.08 | -1.23 | -0.94 |
| DilutedNIAvailtoComStockholders | -130.30M | -101.74M | -108.18M | -58.23M |
| NetIncomeCommonStockholders | -130.30M | -101.74M | -108.18M | -58.23M |
| NetIncome | -130.30M | -101.74M | -108.18M | -58.23M |
| NetIncomeIncludingNoncontrollingInterests | -130.30M | -101.74M | -108.18M | -58.23M |
| NetIncomeContinuousOperations | -130.30M | -101.74M | -108.18M | -58.23M |
| TaxProvision | 208.00K | 134.00K | 54.00K | 292.00K |
| PretaxIncome | -130.09M | -101.61M | -108.12M | -57.94M |
| OtherIncomeExpense | 7.61M | 5.94M | 1.49M | -248.00K |
| OtherNonOperatingIncomeExpenses | 7.61M | 5.94M | 1.49M | -248.00K |
| NetNonOperatingInterestIncomeExpense | 7.89M | 6.62M | 1.46M | 495.00K |
| InterestIncomeNonOperating | 7.89M | 6.62M | 1.46M | 495.00K |
| OperatingIncome | -145.59M | -114.17M | -111.07M | -58.19M |
| OperatingExpense | 187.66M | 150.70M | 135.93M | 95.23M |
| ResearchAndDevelopment | 143.92M | 115.20M | 105.91M | 77.64M |
| SellingGeneralAndAdministration | 43.75M | 35.50M | 30.02M | 17.60M |
| GeneralAndAdministrativeExpense | 43.75M | 35.50M | 30.02M | 17.60M |
| OtherGandA | 43.75M | 35.50M | 30.02M | 17.60M |
| TotalRevenue | 42.07M | 36.53M | 24.86M | 37.04M |
| OperatingRevenue | 42.07M | 36.53M | 24.86M | 37.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 107.73M | 102.20M | 88.18M | 87.60M |
| ShareIssued | 107.73M | 102.20M | 88.18M | 87.60M |
| TotalDebt | 36.49M | 38.92M | 41.13M | 1.50M |
| TangibleBookValue | 199.52M | 253.11M | 249.48M | 344.75M |
| InvestedCapital | 199.52M | 253.11M | 249.48M | 344.75M |
| WorkingCapital | 228.17M | 300.60M | 319.73M | 451.65M |
| NetTangibleAssets | 199.52M | 253.11M | 249.48M | 344.75M |
| CapitalLeaseObligations | 36.49M | 38.92M | 41.13M | 1.50M |
| CommonStockEquity | 199.52M | 253.11M | 249.48M | 344.75M |
| TotalCapitalization | 199.52M | 253.11M | 249.48M | 344.75M |
| TotalEquityGrossMinorityInterest | 199.52M | 253.11M | 249.48M | 344.75M |
| StockholdersEquity | 199.52M | 253.11M | 249.48M | 344.75M |
| GainsLossesNotAffectingRetainedEarnings | 336.00K | 186.00K | -3.71M | -765.00K |
| OtherEquityAdjustments | 336.00K | 186.00K | -3.71M | -765.00K |
| RetainedEarnings | -501.56M | -371.26M | -269.51M | -161.34M |
| AdditionalPaidInCapital | 700.63M | 624.08M | 522.61M | 506.76M |
| CapitalStock | 108.00K | 102.00K | 88.00K | 88.00K |
| CommonStock | 108.00K | 102.00K | 88.00K | 88.00K |
| TotalLiabilitiesNetMinorityInterest | 116.97M | 149.46M | 186.99M | 155.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 78.81M | 103.52M | 131.45M | 114.72M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 44.77M | 66.68M | 92.09M | 114.72M |
| NonCurrentDeferredRevenue | 44.77M | 66.68M | 92.09M | 114.72M |
| LongTermDebtAndCapitalLeaseObligation | 34.04M | 36.84M | 39.36M | 0.00 |
| LongTermCapitalLeaseObligation | 34.04M | 36.84M | 39.36M | 0.00 |
| CurrentLiabilities | 38.17M | 45.94M | 55.55M | 40.69M |
| OtherCurrentLiabilities | 1.74M | 1.29M | 1.27M | 666.00K |
| CurrentDeferredLiabilities | 17.62M | 25.67M | 31.79M | 26.02M |
| CurrentDeferredRevenue | 17.62M | 25.67M | 31.79M | 26.02M |
| CurrentDebtAndCapitalLeaseObligation | 2.45M | 2.08M | 1.77M | 1.50M |
| CurrentCapitalLeaseObligation | 2.45M | 2.08M | 1.77M | 1.50M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.69M | |||
| PayablesAndAccruedExpenses | 16.36M | 16.90M | 20.72M | 12.50M |
| CurrentAccruedExpenses | 14.76M | 14.11M | 16.23M | 9.22M |
| Payables | 1.60M | 2.79M | 4.49M | 3.28M |
| TotalTaxPayable | 0.00 | 35.00K | 52.00K | |
| IncomeTaxPayable | 0.00 | 35.00K | 52.00K | |
| AccountsPayable | 1.60M | 2.79M | 4.45M | 3.23M |
| TotalAssets | 316.49M | 402.57M | 436.47M | 500.15M |
| TotalNonCurrentAssets | 50.15M | 56.03M | 61.20M | 7.82M |
| OtherNonCurrentAssets | 2.57M | 2.61M | 3.43M | 1.73M |
| NetPPE | 47.58M | 53.42M | 57.77M | 6.09M |
| AccumulatedDepreciation | -8.36M | -5.99M | -3.68M | -2.53M |
| GrossPPE | 55.94M | 59.41M | 61.45M | 8.62M |
| Leases | 2.87M | 2.86M | 2.78M | 246.00K |
| ConstructionInProgress | 152.00K | 38.00K | 8.00K | 738.00K |
| OtherProperties | 48.41M | 52.30M | 54.61M | 6.84M |
| MachineryFurnitureEquipment | 4.51M | 4.21M | 4.06M | 790.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 266.34M | 346.54M | 375.27M | 492.34M |
| OtherCurrentAssets | 8.43M | 8.80M | 6.57M | 4.52M |
| RestrictedCash | 0.00 | 856.00K | 567.00K | 567.00K |
| PrepaidAssets | 4.52M | |||
| Receivables | 0.00 | 2.00M | 2.00M | |
| AccountsReceivable | 0.00 | 2.00M | 2.00M | |
| CashCashEquivalentsAndShortTermInvestments | 257.92M | 336.88M | 366.13M | 485.25M |
| OtherShortTermInvestments | 188.39M | 270.50M | 306.17M | 342.51M |
| CashAndCashEquivalents | 69.53M | 66.39M | 59.97M | 142.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -132.25M | -119.51M | -116.77M | -61.36M |
| IssuanceOfDebt | 0.00 | 342.11M | ||
| IssuanceOfCapitalStock | 41.72M | 80.02M | 0.00 | 29.99M |
| CapitalExpenditure | -754.00K | -1.53M | -7.69M | -1.84M |
| EndCashPosition | 72.10M | 69.81M | 63.96M | 145.02M |
| BeginningCashPosition | 69.81M | 63.96M | 145.02M | 30.66M |
| ChangesInCash | 2.29M | 5.85M | -81.07M | 114.36M |
| FinancingCashFlow | 47.66M | 82.41M | 1.61M | 357.32M |
| CashFlowFromContinuingFinancingActivities | 47.66M | 82.41M | 1.61M | 357.32M |
| NetOtherFinancingCharges | 448.00K | -8.00K | -15.84M | |
| ProceedsFromStockOptionExercised | 5.94M | 1.94M | 1.62M | 1.06M |
| NetPreferredStockIssuance | 0.00 | 29.99M | ||
| PreferredStockIssuance | 0.00 | 29.99M | ||
| NetCommonStockIssuance | 41.72M | 80.02M | 0.00 | |
| CommonStockIssuance | 41.72M | 80.02M | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | 342.11M | ||
| NetLongTermDebtIssuance | 0.00 | 342.11M | ||
| LongTermDebtIssuance | 0.00 | 342.11M | ||
| InvestingCashFlow | 86.13M | 41.43M | 26.40M | -183.43M |
| CashFlowFromContinuingInvestingActivities | 86.13M | 41.43M | 26.40M | -183.43M |
| NetInvestmentPurchaseAndSale | 86.88M | 42.95M | 34.09M | -181.60M |
| SaleOfInvestment | 327.77M | 353.53M | 242.59M | 190.76M |
| PurchaseOfInvestment | -240.89M | -310.57M | -208.50M | -372.36M |
| NetPPEPurchaseAndSale | -754.00K | -1.53M | -7.69M | -1.84M |
| PurchaseOfPPE | -754.00K | -1.53M | -7.69M | -1.84M |
| OperatingCashFlow | -131.50M | -117.98M | -109.08M | -59.53M |
| CashFlowFromContinuingOperatingActivities | -131.50M | -117.98M | -109.08M | -59.53M |
| ChangeInWorkingCapital | -31.75M | -37.97M | -18.49M | -11.35M |
| ChangeInOtherWorkingCapital | -29.97M | -31.53M | -16.86M | -12.04M |
| ChangeInOtherCurrentLiabilities | -2.14M | -2.44M | 1.70M | -1.07M |
| ChangeInOtherCurrentAssets | 43.00K | -41.00K | -10.00M | -139.00K |
| ChangeInPayablesAndAccruedExpense | -50.00K | -3.73M | 8.73M | 5.06M |
| ChangeInAccruedExpense | 1.13M | -2.03M | 7.63M | 3.83M |
| ChangeInPayable | -1.18M | -1.71M | 1.10M | 1.23M |
| ChangeInAccountPayable | -1.18M | -1.71M | 1.10M | 1.23M |
| ChangeInPrepaidAssets | 370.00K | -2.23M | -2.06M | -3.16M |
| ChangeInReceivables | 0.00 | 2.00M | 0.00 | 0.00 |
| ChangesInAccountReceivables | 0.00 | 2.00M | 0.00 | 0.00 |
| OtherNonCashItems | 3.77M | 3.63M | 1.75M | 1.32M |
| StockBasedCompensation | 28.90M | 19.08M | 14.23M | 7.83M |
| AmortizationOfSecurities | -4.62M | -3.39M | 0.00 | |
| DepreciationAmortizationDepletion | 2.50M | 2.42M | 1.61M | 897.00K |
| DepreciationAndAmortization | 2.50M | 2.42M | 1.61M | 897.00K |
| Depreciation | 2.50M | 2.42M | 1.61M | 897.00K |
| NetIncomeFromContinuingOperations | -130.30M | -101.74M | -108.18M | -58.23M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TNGX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|